Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics.
The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial.
The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform. This integration could accelerate the development of new therapies by leveraging advanced data analysis.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
The Deciparticle(TM) platform represents a significant advancement in drug delivery, potentially improving the therapeutic index of existing drugs and enabling new treatments for conditions that were previously difficult to address due to solubility issues. The progress of Sapu006 and Sapu003 into Phase 1b trials underscores the translational potential of this technology.
For more details, visit the full press release at https://ibn.fm/RUG7m. Information about Oncotelic is available at https://ibn.fm/OTLC.
